Orum Therapeutics Venture Capital
Founded 2016 · 55 employees on LinkedIn · Public · 5 known investors
Find your way into Orum Therapeutics Venture Capital
611 people in our graph share verified history with the Orum Therapeutics Venture Capital team — schools, employers, funds. One of them is your warm intro.
.jpeg)
Orum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.
Also known as Orum · Orum Therapeutics
Founders & leadership
Orum Therapeutics Venture Capital was founded in 2016 by SJ Lee.
Investors · 5
Company profile
researched Aug 2026Orum Therapeutics is a biotechnology company developing degrader-antibody conjugates (DACs), a class of antibody-drug conjugate in which a targeted protein degrader payload is conjugated to an antibody. The company describes its platform as Dual-Precision Targeted Protein Degradation (TPD²), which combines newly developed protein degrader payloads that eliminate an intracellular target protein through the E3 ubiquitin ligase pathway with the cell-delivery specificity of antibodies. The stated aim of this cell-selective approach is to improve efficacy, safety and half-life relative to conventional targeted protein degraders, and to expand the range of druggable targets.
Orum is a clinical-stage company advancing GSPT1-directed TPD² programs alongside work on additional novel degrader payloads. Its lead disclosed candidate, ORM-1153, is a CD123-GSPT1 DAC intended for relapsed or refractory acute myeloid leukemia (AML) and other hematologic malignancies. The company trades on the Korea Exchange under the ticker 475830 and operates from Daejeon, South Korea and Lexington, Massachusetts, United States.
Business model
Orum develops proprietary oncology therapeutics in-house, advancing candidates from preclinical research through clinical trials as a publicly listed biotechnology company.
Traction
ORM-1153 preclinical data presented at the AACR Annual Meeting 2026 showed activity across AML models, including primary AML patient samples and TP53-relevant models, low-dose in vivo activity and favorable repeat-dose tolerability. The FDA cleared the IND application for ORM-1153 in August 2026, with a first-in-human Phase 1 study of approximately 42 patients planned to begin by the end of 2026.
Latest developments
In August 2026 Orum announced U.S. FDA clearance of the IND for ORM-1153 and scheduled a conference call to review the clearance and the Phase 1 study design. Earlier in 2026 the company presented ORM-1153 preclinical data at AACR and appointed Dr. Maria Koehler and Geoff Meyerson to its board of directors.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Orum positions itself as a pioneer of the degrader-antibody conjugate field, describing its candidates as first-in-class, cell-selective targeted protein degraders and a novel class of ADCs.
Orum's approach differs from conventional targeted protein degraders by adding antibody-mediated cell selectivity, which the company states is designed to improve efficacy, safety and half-life, and differs from conventional ADCs by using a protein degrader rather than a cytotoxic payload.
Technology
The company's TPD² (Dual-Precision Targeted Protein Degradation) approach conjugates proprietary targeted protein degrader payloads to antibodies, so that the payload is delivered specifically to target cells and degrades an intracellular protein of interest via the E3 ubiquitin ligase pathway. Current disclosed programs are GSPT1-directed; ORM-1153 delivers a GSPT1 degrader payload to CD123-expressing cells and uses an optimized antibody and linker design.
Go-to-market
Patients with cancer, initially those with relapsed or refractory acute myeloid leukemia and other hematologic malignancies, treated at multicenter clinical sites.
Geography
Orum operates from Daejeon, South Korea and Lexington, Massachusetts, with press releases datelined Boston and Daejeon. The planned Phase 1 study of ORM-1153 will begin at U.S. clinical sites with potential expansion to other regions.
Risks & controversies
Company forward-looking statements cite risks including uncertainty in research and development, clinical trial delays, safety issues, enrollment challenges or negative results, competition from alternative therapies, regulatory review and approval risk, reliance on third-party manufacturing and development, key-employee retention, market conditions and future fundraising needs.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsThe U.S. FDA cleared Orum's Investigational New Drug application for ORM-1153. Orum plans to start a first-in-human Phase 1 study in relapsed or refractory AML and other hematologic malignancies by the end of 2026, enrolling approximately 42 patients initially at U.S. sites.
Preclinical data showed improved pharmacology from optimized antibody and linker design, low-dose in vivo activity, favorable repeat-dose tolerability, activity across primary AML patient samples and retained activity in TP53-relevant models.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- Orum Therapeutics Venture Capitalorumrx.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Orum Therapeutics Venture Capital do?
- Clinical-stage biotech developing degrader-antibody conjugates that pair targeted protein degraders with antibodies for oncology.
- Who founded Orum Therapeutics Venture Capital?
- Orum Therapeutics Venture Capital was founded by SJ Lee in 2016.
- Who are Orum Therapeutics Venture Capital's investors?
- Orum Therapeutics Venture Capital's investors include Atinum Investment Co. Ltd., IMM Investment Japan, LB Investment, Solidus Investment, Xquared VC.